We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
- Authors
Hsieh, Chen-Hsi; Chang, Hou-Tai; Lin, Shih-Chiang; Chen, Yu-Jen; Wang, Li-Ying; Hsieh, Yen-Ping; Chen, Chien-An; Chong, Ngot-Swan; Lin, Shoei Long; Chen, Chun-Yi; Shueng, Pei-Wei
- Abstract
<bold>Background: </bold>Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously.<bold>Case Presentation: </bold>A 77-year-old man with stage III NSCLC, received erlotinib 150 mg/day, combined with image-guided SBRT via HT. A total tumor dose of 54 Gy/9 fractions was delivered to the tumor bed. The tumor responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy and radiation pneumonitis with interstitial lung disease was suspected.<bold>Conclusions: </bold>Combination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially when SBRT is part of the regimen.
- Publication
BMC Cancer, 2010, Vol 10, p696
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/1471-2407-10-696